The invention concerns a mixture of peptides derived from the E6 and/or E7
proteins of a papillomavirus involved in cervix of uterus cancer, such as
HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40,
HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57, and HPV58, for
example, as well as its uses as medicine (in immunogenic compositions,
capable of stimulating the production of anti-HPV T CD4+ lymphocytes in
vivo and hence useful for vaccination against uterine of uterus cancer
and in other cancers) or as diagnostic reagent of HPV-specific T
lymphocytes, in particular for assessing the immune condition of
patients. The invention also concerns a mixture of peptides derived from
E6 and/or E7 proteins of a papillomavirus involved in benign skin lesions
(for example warts), such as HPV10, HPV3 or HPV4 and its uses as
medicine.